


FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/585,464		ATTY. DOCKET NO.: C1285.70006US01	
				FILING DATE: May 3, 2007		CONFIRMATION NO.: 5882	
				APPLICANT: Marsha A. Moses			
				GROUP ART UNIT: 1643		EXAMINER: A. M. HARRIS	
Sheet	1	of	4				



U.S. PATENT DOCUMENTS

Examiner's Initials #	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
		7,060,791	B2	Fujisawa et al.	06-13-2006

FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
		EP	0933423	B1	Mochida Pharmaceutical Co., Ltd.	10-17-1996	
		WO	97/40072	A2	The University of Sheffield	10-30-1997	
		WO	02/059377	A2	EOS Biotechnology, Inc.	08-01-2002	

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		IBA et al. "Cysteine-rich domain of human ADAM 12 (Meltrin α) supports tumor cell adhesion," <i>Am. J. of Pathol.</i> , vol. 154, no. 5 (May 1999) 1489-1501.	
		TIAN et al. "The expression of ADAM 12 (meltrin α) in human giant cell tumours of bone", <i>J. Clin. Pathol.: Mol. Pathol.</i> , vol. 55 (2002) 394-397.	
		PABIC et al. "ADAM12 in human liver cancers: TGF- β -regulated expression in stellate cells is associated with matrix remodeling", <i>Hepatology</i> , vol. 37, no. 5 (2003) 1056-1066.	
		"Cellular, Molecular, and tumor biology 62: biomarkers for metastasis," <i>Proc. Amer. Assoc. Cancer Res.</i> , vol. 45 (2004).	Abstract
		HOSAKA et al. "Mortality of rat ascites hepatoma cells, with reference to malignant characteristics in cancer metastasis", vol. 69, no. 2 (April 1978) 273-6.	Abstract
		HAEMMERLI et al. "In vitro motility of cells from human epidermoid carcinomas. A study by phase-contrast and reflection-contrast cinematography," <i>Int. J. Cancer</i> , vol. 27, no. 5 (May 15, 1981) 603-10.	Abstract
		LEPABIC et al. "ADAM12 in human liver cancers: TGF-beta-regulated expression in stellate cells is associated with matrix remodeling," <i>Hepatology</i> , vol. 37, no. 5 (May 2003) 1056-66.	Abstract
		PARKIN et al. "Global cancer statistics," <i>CA Cancer J. Clin.</i> , vol. 55, no. 2 (March-April 2005) 74-108.	Abstract
		JEMAL et al. "Cancer statistics," <i>CA Cancer J. Clin.</i> , vol. 55, no. 1 (Jan-Feb. 2005) 10-30.	Abstract
		MOSES et al. "Increased incidence of matrix metalloproteinases in urine of cancer patients" <i>Can. Research</i> , vol. 58 (April 1, 1998) 1395-1399.	
		YAN et al. "The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase activity B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL)" <i>J. Biol. Chem.</i> , vol. 276, issue 40 (October 5, 2001) 37258-37265.	
		GILPIN et al. "A novel, secreted form of human ADAM 12 (meltrin α) provokes myogenesis in vivo," <i>J. of Biol. Chem.</i> , vol. 273, no.1, (January 2, 1998) 157-166.	
		LACQUEMENT et al. "Positive predictive value of the breast imaging reporting and data system," <i>J. Am. Coll. Surg.</i> , vol. 189, no. 1 (July 1999) 34-40.	Abstract
		HOLLINGSWORTH et al. "Current comprehensive assessment and management of women at increased risk for breast cancer," <i>Am. J. Surg.</i> , vol. 187, no. 3, (March 2004) 349-62.	Abstract
		POULSOM et al. "Expression of gelatinase A and TIMP-2 mRNAs in desmoplastic fibroblasts in both mammary carcinomas and basal cell carcinomas of the skin," <i>J. Clin. Pathol.</i> , vol. 46, no. 5 (May 1993) 429-36.	Abstract

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/585,464	ATTY. DOCKET NO.: C1285.70006US01
				FILING DATE: May 3, 2007	CONFIRMATION NO.: 5882
				APPLICANT: Marsha A. Moses	
				GROUP ART UNIT: 1643	EXAMINER: A. M. HARRIS
Sheet	2	of	4		

	BROWN et al. "Expression of activated gelatinase in human invasive breast carcinoma," <i>Clin. Exp. Metastasis</i> , vol. 11, no. 2 (March 1993) 183-9.	Abstract
	ZUCKER et al. "Plasma assay of gelatinase B: tissue inhibitor of metalloproteinase complexes in cancer," <i>Cancer</i> , vol. 76, no. 4, (August 15, 1995) 700-8.	Abstract
	NGUYEN et al. "Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers," <i>J. Natl. Cancer Inst.</i> , vol. 86, no. 5, (March 2, 1994) 356-61.	Abstract
	GERHARDS et al. "Excretion of matrix metalloproteinases 2 and 9 in urine is associated with a high stage and grade of bladder carcinoma," <i>Urology</i> , vol. 57, no. 4, (April 2001) 675-9.	Abstract
	SIER et al. "Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: a comparison with clinically used tumor markers," <i>Clin. Cancer Res.</i> , vol. 6, no. 6, (June 2000) 2333-40.	Abstract
	KANAYAMA, "Matrix metalloproteinase and bladder cancer," <i>J. Med. Invest.</i> , vol. 48, no. 1-2, (February 2001) 31-43.	Abstract
	HANEMAAIJER et al. "MMP-9 activity in urine from patients with various tumors, as measured by a novel MMP activity assay using modified urokinase as a substrate," <i>Ann. N.Y. Acad. Sci.</i> , vol. 878 (June 30, 1999) 141-9.	Abstract
	MONIER et al. "Urinary release of 72 and 92 kDa gelatinase, TIMPs, N-GAL and conventional prognostic factors in urothelial carcinomas," <i>Eur. Urol.</i> , vol. 42, no. 4 (October 2002) 356-63.	Abstract
	NUTT et al. "Matrix metalloproteinases (MMPs) in bladder cancer: the induction of MMP9 by epidermal growth factor and its detection in urine," <i>BJU Int.</i> , vol. 91, no. 1, (January 2003) 99-104.	Abstract
	SHERIEF et al. "Matrix metalloproteinase activity in urine of patients with renal cell carcinoma leads to degradation of extracellular matrix proteins: possible use as a screening assay," <i>J. Urol.</i> , vol. 169, no. 4 (April 2003) 1530-4.	Abstract
	DURKAN et al. "Prognostic significance of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder," <i>Clin. Cancer Res.</i> , vol. 7, no. 11 (November 2001) 3450-6.	Abstract
	FANG et al. "Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model," <i>Proc. Natl. Acad. Sci. U.S.A.</i> , vol. 97, no. 8 (April 11, 2000) 3884-9.	Abstract
	ROY et al. "ADAM 12 cleaves extracellular matrix proteins and correlates with cancer status and stage," <i>J. of Biol. Chem.</i> , vol. 279, no. 49 (December 3, 2004) 51323-51330.	
	MARSHALL et al. "Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types ¹ ," <i>Can. Epidemiology, Biomarkers & Prevention</i> , vol. 6, (May 1997) 297-301.	
	DUPONT et al. "Risk factors for breast cancer in women with proliferative breast disease," <i>N. Engl. J. Med.</i> , (vol. 312, no. 3 (January 17, 1985) 146-51.	Abstract
	LI et al. "Changing incidence of lobular carcinoma in situ of the breast," <i>Breast Can. Res. Treat.</i> , vol. 75, no. 3 (October 2002) 259-68.	Abstract
	FISHER et al. "Pathologic findings from the national surgical adjuvant breast bowel project: twelve-year observations concerning lobular carcinoma in situ," <i>Cancer</i> , vol. 100, no. 2 (January 15, 2004) 238-44.	Abstract
	SNEIGE et al. "Clinical, histopathologic, and biologic features of pleomorphic lobular (ductal-lobular) carcinoma in situ of the breast: a report of 24 cases," <i>Mod. Pathol.</i> , vol. 15, no. 10 (October 2002) 1044-50.	Abstract
	MIDDLETON et al. "Pleomorphic lobular carcinoma: morphology, immunohistochemistry, and molecular analysis," <i>Am. J. Surg. Pathol.</i> , vol. 24, no. 12 (December 2000) 1650-6.	Abstract
	PAGE et al. "A typical hyperplastic lesions of the female breast. A long-term follow-up study," <i>Cancer</i> , vol. 55, no. 11 (June 1, 1985) 2698-708.	Abstract
	HARTMANN et al. "Benign breast disease and the risk of breast cancer," <i>N. Engl. J. Med.</i> , vol 353, no. 3 (July 21, 2005) 229-37.	Abstract

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/585,464	ATTY. DOCKET NO.: C1285.70006US01
				FILING DATE: May 3, 2007	CONFIRMATION NO.: 5882
				APPLICANT: Marsha A. Moses	
				GROUP ART UNIT: 1643	EXAMINER: A. M. HARRIS
Sheet	3	of	4		

		RENSHAW "Improved reporting methods for atypia and atypical ductal hyperplasia in breast core needle biopsy specimens. Potential for interlaboratory comparisons," <i>Am. J. Clin. Pathol.</i> , vol. 116, no. 1 (July 2001) 87-91.	Abstract
		ERNSTER et al. "Detection of ductal carcinoma in situ in women undergoing screening mammography" <i>J. Natl. Cancer Inst.</i> , vol. 94, no. 20 (October 16, 2002) 1546-54.	Abstract
		HOOGERBRUGGE et al. "High prevalence of premalignant lesions in prophylactically removed breasts from women at hereditary risk for breast cancer," <i>J. Clin. Oncol.</i> , vol. 21, no. 1 (January 1, 2003) 41-5.	Abstract
		ELMORE et al. "Efficacy of breast cancer screening in the community according to risk level," <i>J. Natl. Cancer Inst.</i> , vol. 97, no. 14 (July 20, 2005) 1035-43.	Abstract
		PISANO et al. "Diagnostic performance of digital versus film mammography for breast-cancer screening," <i>N. Engl. J. Med.</i> , vol. 353, no. 17 (October 27, 2005) 1773-83. <i>Epub 09-16-2005.</i>	Abstract
		BERRY et al. "Effect of screening and adjuvant therapy on mortality from breast cancer," <i>N. Engl. J. Med.</i> , vol. 353, no. 17 (October 27, 2005) 1784-92.	Abstract
		BARLOW et al. "Performance of diagnostic mammography for women with signs or symptoms of breast cancer," <i>J. Natl. Cancer Inst.</i> , vol. 94, no. 15 (August 7, 2002) 1151-9.	Abstract
		MAJID et al. "Missed breast carcinoma: pitfalls and pearls," <i>Radiographics</i> , vol. 23, no. 4 (July-August 2003) 881-95.	Abstract
		BROWN et al. "Screening mammography in community practice: positive predictive value of abnormal findings and yield of follow-up diagnostic procedures," <i>AJR Am. J. Roentgenol.</i> , vol. 165, no. 6, (December 1995) 1373-7.	Abstract
		FOX et al. "The impact of physician compliance on screening mammography for older women," <i>Arch. Intern. Med.</i> , vol. 151, no. 1 (January 1991) 50-6.	Abstract
		RIMER et al. "Older women's participation in breast screening," <i>J. Gerontol.</i> , Spec. No. 47, (November 1992) 85-91.	Abstract
		SMITH et al. "American cancer society guidelines for the early detection of cancer," <i>CA Cancer J. Clin.</i> , vol. 55, no. 1, (January-February 2005) 31-44; <i>quiz 55-6.</i>	Abstract
		GEORGE "Barriers to breast cancer screening: an integrative review," <i>Health Care Women Int.</i> , vol. 21, no. 1 (January-February 2000) 53-65.	Abstract
		HAMILTON et al. "Women's views of a breast screening service," vol. 24, no. 1 (January 2003) 40-8.	Abstract
		CONSEDINE et al. "The contribution of emotional characteristics to breast cancer screening among women from six ethnic groups," <i>Prev. Med.</i> , vol. 38, no. 1 (January 2004) 64-77.	Abstract
		FISHER et al. "Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study," <i>J. Natl. Cancer Inst.</i> , vol. 90, no. 18 (September 16, 1998) 1371-88.	Abstract
		CUMMINGS et al. "The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation," <i>JAMA</i> , vol. 281, no. 23 (June 16, 1999) 2189-97.	Abstract
		VOGEL et al. "The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial," <i>Clin. Breast Cancer</i> , vol. 3, no. 2 (June 2002) 153-9.	Abstract
		WICKERHAM "Tamoxifen's impact as a preventative agent in clinical practice and an update on the STAR trial," <i>Recent Results Cancer Res.</i> , vol. 163 (2003) 87-95; <i>discussion 264-6.</i>	Abstract
		WICKERHAM "Tamoxifen versus raloxifene in the prevention of breast cancer," <i>Eur. J. Cancer</i> , vol. 38, suppl. 6 (November 2002) S20-1.	Abstract
		CUZICK "Aromatase inhibitors for breast cancer prevention," <i>J. Clin. Oncol.</i> , vol. 23, no. 8 (March 10, 2005) 1636-1643.	
		GOSS "Breast cancer prevention—clinical trials strategies involving aromatase inhibitors," <i>J. Steroid Biochem. Mol. Biol.</i> , vol. 86, no. 3-5 (September 2003) 487-93.	Abstract
		GOSS et al. "Prevention strategies with aromatase inhibitors," <i>Clin. Cancer Res.</i> , vol. 10 (1 Pt. 2) (January 1, 2004) 372S-9S.	Abstract

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/585,464	ATTY. DOCKET NO.: C1285.70006US01
				FILING DATE: May 3, 2007	CONFIRMATION NO.: 5882
				APPLICANT: Marsha A. Moses	
				GROUP ART UNIT: 1643	EXAMINER: A. M. HARRIS
Sheet	4	of	4		

		GOSS et al. "Aromatase inhibitors for chemoprevention," <i>Best Pract. Res. Clin. Endocrinol. Metab.</i> , vol. 18, no. 1 (March 2004) 113-30.	Abstract
		GAIL et al. "Projecting individualized probabilities of developing breast cancer for white females who are being examined annually," <i>J. Natl. Cancer Inst.</i> , vol. 81, no. 24 (December 20, 1989) 1879-86.	Abstract
		CLAUS et al. "Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction," <i>Cancer</i> , vol. 73, no. 3 (February 1, 1994) 643-51.	Abstract
		BERRY et al. "BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes," <i>J. Clin. Oncol.</i> , vol. 20, no. 11 (June 1, 2002) 2701-12.	Abstract
		POOLA et al. "Identification of MMP-1 as a putative breast cancer predictive marker by global gene expression analysis," <i>Nat. Med.</i> , vol. 11, no. 5 (May 2005) 481-3. <i>Epub 05-01-2005.</i>	Abstract
		WURTZ et al. "Tissue inhibitor of metalloproteinases-1 in breast cancer," <i>Endocr. Relat Cancer</i> , vol. 12, no. 2 (June 2005) 215-27.	Abstract
		COSTANTINO et al. "Validation studies for models projecting the risk of invasive and total breast cancer incidence," <i>J. Natl. Cancer Inst.</i> , vol. 91, no. 18 (September 15, 1999) 1541-8.	Abstract

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]